Obesity, cardiovascular diseases
Conditions
Interventions
For all subjects on both study days the intervention consists of intravenous (IV) injection of salbutamol. This will be combined with either placebo (day 1 or 2) or propranolol (day 1 or 2) oral capsu
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: - Dutch white Caucasian males - Age between 18-35 years old - Lean (BMI = 18 and = 25 kg/m2)
Exclusion criteria
Exclusion criteria: - Diabetes mellitus (determined on basis of fasting glucose levels defined by ADA criteria) - Any other active endocrine disease (thyroid disease, any signs of Cushing’s syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia) - Any cardiac disease (i.e. ischemic cardiac disease, arrhythmias, severe heart failure) - A first-degree family member with sudden cardiac death - Any chronic renal or hepatic disease - Use of beta-adrenergic receptor agonists (for e.g. asthma) - Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g. beta-blockers, antidepressants, corticosteroids) - Use of medication shown to increase risk on hypokalemia after salbutamol administration (e.g. xanthine derivatives, steroids and diuretics) - Any other contra-indications for the use of salbutamol or propranolol - Abuse of alcohol or other substances - Smoking - Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study - Current participation in another research projects that may influence the current research project - Participation in another research with exposure to radiation burden within a year before the start of the current study - Clinically relevant abnormalities in clinical chemistry or electrocardiogram (ECG) at screening (to be judged by the study physician)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose uptake by BAT, as measured by dynamic [18F]FDG PET/CT acquisition | — |
Secondary
| Measure | Time frame |
|---|---|
| - Resting energy expenditure, as measured by indirect calorimetry - Serum markers for lipid metabolism (triglycerides (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acids) - Lipid pathway analysis using lipidomic analysis in plasma samples - Serum markers for glucose metabolism (glucose, insulin) - Circulating plasma BAT markers (e.g. microRNAs) | — |
Contacts
Public ContactMaaike Straat
Leiden Universitair Medisch Centrum
Outcome results
None listed